|
|
 |
|
|
|
| Speakers include: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr. Iman El-Hariry, Group Director, Oncology MDC, Europe, GlaxoSmithKline R&D
|
|
|
|
Dr. Dorothee Foernzler, Biomarker - Experimental Medicine Leader F.Hoffmann-La Roche
|
|
|
|
Dr. Stuart Freeman, Director of Worldwide Toxicology, GlaxoSmithKline UK
|
|
|
|
Dr. Nicolas Frey, Head of the Modeling and Simulation Group, F. Hoffmann-La Roche
|
|
|
|
Dr. William Gallagher, Associate Professor, University College Dublin
|
|
|
|
Antony Gee, Head of PET and Radiotracer Development, GlaxoSmithKline
|
|
|
|
Dr. Martin Grigorov, Head of Bioinformatics, Nestle Research Centre
|
|
|
|
Dr. Ehud Hauben, Head of Molecular Medicine Unit, Clinical Sciences and Biomarkers, Exploratory Medicine, Merck Serono Research
|
|
|
|
Dr. Hermann-Josef Huss, Head, Data Acquisition & Management Europe & Overseas, Bayer Healthcare
|
|
|
|
Dr. Jeanne Kehren, Head of Integrated Analysis, Biomarker Development, Novartis Pharma AG
|
|
|
|
Dr. Bernard Leblanc, Head, Regulatory Submissions & External Relations Safety Sciences, Pfizer
|
|
|
|
Dr. Ruth March, Personalized Healthcare Science & Technology Director, Personalized Healthcare Team, Astra Zeneca UK
|
|
|
|
Prof. Dario Neri, Professor, Department of Chemistry and Applied Biosciences ETH Zurich
|
|
|
|
Dr. Martin Oleksiewicz, Team Leader, Molecular Toxicology, Novo Nordisk A/S
|
|
|
|
Dr. Koustubh Ranade, Director, Pharmacogenomics & Human Genetics, Pharmaceutical Research Institute, Bristol-Myers Squibb Company
|
|
|
|
Dr. Bjorn Riefke, Head Laboratory Diagnostics Non-Clinical Drug Safety, Bayer Healthcare
|
|
|
|
Dr. Ronenn Roubenoff, MD, Senior Director, Immunology Medical Research, Biogen Idec, Inc.
|
|
|
|
Dr. Hugh Salter, Associate Director, Pharmacogenomics, Astra Zeneca
|
|
|
|
Dr. Michael Shi, Director and Biomarker Project Leader of Exploratory Oncology Development, Novartis
|
|
|
|
Dr. Magnus Sjogren, Associate Professor, Psychiatrist, Director Clinical Research CNS, N.V. Organon
|
|
|
|
Dr. Thomas Steger-Hartmann, Head Lab Diagnostics Experimental Toxicology, Schering AG
|
|
|
|
Dr. Detlef Stiller, Head, Invivo Imaging, Boehringer Ingelheim Germany
|
|
|
|
Dr. Stefan Sultana, Translational Medicine Leader for GU Therapeutic Area, Pfizer
|
|
|
|
Jean Tessier, Clinical Imaging Scientist, Discovery Medicine, Astra Zeneca
|
|
|
|
Dr. Alain van Gool, Director Genomics & Proteomics N.V. Organon
|
|
|
|
Dr. George Wensing, Head, Pharmacodynamics, Clinical Pharmacology, Bayer Healthcare
|
|
|
|
Dr. Paul Whiting, Head of Biomarkers and Translational Biology, Discovery Biology, Pfizer
|
|
|
|
|
|
|
|
Speakers
